AI brief of an SEC Form 8-K · Inspire Medical Systems (INSP)

Inspire Medical Systems cuts 2026 revenue outlook to $825 million-$875 million

Mixed Impact 4 of 5 guidance Written later

Inspire Medical Systems reported first-quarter 2026 revenue of $204.6 million, up 1.6% from a year earlier, but posted a net loss of $11.3 million, or $(0.39) per diluted share, compared with earnings of $0.10 per diluted share a year earlier. The company lowered its full-year 2026 revenue outlook to $825 million-$875 million, a decline of 4% to 10% from 2025, and said it expects coding and reimbursement uncertainty for Inspire V to persist through the rest of 2026.

Key points

  • Q1 2026 revenue rose 1.6% to $204.6 million; GAAP diluted EPS was $(0.39) versus $0.10 a year earlier.
  • Adjusted diluted EPS was $0.10; the company reported a $11.3 million net loss, which includes a $13.1 million tax impact of stock-based compensation.
  • 2026 revenue guidance revised to $825 million-$875 million; diluted EPS guidance of $0.07-$0.62 and adjusted diluted EPS guidance of $0.75-$1.25.
  • Management expects to return to revenue growth in 2027; the earnings call is set for 5:00 p.m. Eastern Time on May 4, 2026.

The filing

CompanyInspire Medical Systems (INSP)
Form8-K, current report
Filed with the SECMay 4, 2026, 4:03 PM ET
Accession number0001609550-26-000021

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.